Home » Howard Robin, John Maraganore, Steve Kriegsman, Bob Towarnicki, John Spears, Dale Pfost, and Sam Reich

Howard Robin, John Maraganore, Steve Kriegsman, Bob Towarnicki, John Spears, Dale Pfost, and Sam Reich

Feb 13, 2004
Premium

The Biotechnology Industry Organization’s annual BIO-CEO conference on Feb. 23-24 is featuring an RNAi discussion panel this year featuring six top industry exectives.

Sirna Therapeutics’ president and CEO Howard Robin is set to present, as is Alnylam Pharmaceuticals’ president and CEO John Maraganore.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Alan Rabson Dies

Cancer researcher Alan Rabson has died at 92, the New York Times reports.

ECRI Institute to Offer Medical Guidelines

As the National Guideline Clearinghouse goes dark, the ECRI Institute says it will pick up the slack.

This Week in Genome Research

In Genome Research this week: sequencing method examines proteins parasite uses to evade immune system, L1 insertions in cancer, and more.

Places to Talk About It

The Atlantic reports on private Facebook support groups for people who receive unexpected parentage results from direct-to-consumer genetic tests.

Aug
07
Featured Webinar

Rapid and Comprehensive NGS Variant Interpretation Using Web-Based Software

Sponsored by
Qiagen

This webinar will present the results of an evaluation of a web-based variant interpretation software system for clinical next-generation sequencing.

What's Popular?

In Gene Silencing/Gene Editing

  1. CRISPR Genome Editing May Cause More Complex Rearrangements, Deletions Than Previously Thought

  2. Inscripta Confirms CRISPR-MAD7 Editing Activity in Mammalian Cells, Releases New MAD2 Enzyme

    Premium

  3. Locus Biosciences Acquires EpiBiome Bacteriophage Discovery Platform

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.